Responses
Clinical/translational cancer immunotherapy
Original research
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
Compose a Response to This Article
Other responses
No responses have been published for this article.
